Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users

被引:66
作者
Schwilke, Eugene W. [1 ]
Gullberg, Rod G. [2 ]
Darwin, William D. [1 ]
Chiang, C. Nora [3 ]
Cadet, Jean Lud [4 ]
Gorelick, David A. [5 ]
Pope, Harrison G. [6 ]
Huestis, Marilyn A. [1 ]
机构
[1] Natl Inst Drug Abuse, Intramural Res Program, NIH, Biomed Res Ctr, Baltimore, MD 21146 USA
[2] Washington State Patrol, Breath Test Sect, Seattle, WA USA
[3] Natl Inst Drug Abuse, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, Rockville, MD USA
[4] Natl Inst Drug Abuse, Intramural Res Program, NIH, Biomed Res Ctr, Baltimore, MD USA
[5] Natl Inst Drug Abuse, Off Sci Director, Intramural Res Program, NIH,Biomed Res Ctr, Baltimore, MD USA
[6] Harvard Univ, McLean Hosp, Belmont, MA 02178 USA
基金
美国国家卫生研究院;
关键词
New cannabis use; predictive model; residual drug excretion; urine cannabinoids; CREATININE RATIO; 11-NOR-9-CARBOXY-DELTA(9)-TETRAHYDROCANNABINOL; PROFILES; DELTA(9)-THC-COOH; MARIJUANA; HUMANS;
D O I
10.1111/j.1360-0443.2010.03228.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To develop and validate empirically a mathematical model for identifying new cannabis use in chronic, daily cannabis smokers. Design Models were based on urinary creatinine-normalized (CN) cannabinoid excretion in chronic cannabis smokers. Setting For model development, participants resided on a secure research unit for 30 days. For model validation, participants were abstinent with daily observed urine specimens for 28 days. Participants A total of 48 (model development) and 67 (model validation) daily cannabis smokers were recruited. Measurements All voided urine was collected and analyzed for 11-nor-9-carboxy-Delta 9-tetrahydrocannabinol (THCCOOH) by gas chromatography-mass spectrometry (GCMS; limit of quantification 2.5 ng/ml) and creatinine (mg/ml). Urine THCCOOH was normalized to creatinine, yielding ng/mg CN-THCCOOH concentrations. Urine concentration ratios were determined from 123 513 specimen pairs collected 2-30 days apart. Findings A mono-exponential model (with two parameters, initial urine specimen CN-THCCOOH concentration and time between specimens), based on the Marquardt-Levenberg algorithm, provided a reasonable data fit. Prediction intervals with varying probability levels (80, 90, 95, 99%) provide upper ratio limits for each urine specimen pair. Ratios above these limits suggest cannabis re-use. Disproportionate numbers of ratios were higher than expected for some participants, prompting development of two additional rules that avoid misidentification of re-use in participants with unusual CN-THCCOOH excretion patterns. Conclusions For the first time, a validated model is available to aid in the differentiation of new cannabis use from residual creatinine-normalized 11-nor-9-carboxy-Delta 9-tetrahydrocannabinol (CN-THCCOOH) excretion in chronic, daily cannabis users. These models are valuable for clinicians, toxicologists and drug treatment staff and work-place, military and criminal justice drug-testing programs.
引用
收藏
页码:499 / 506
页数:8
相关论文
共 18 条
[1]   EXCRETION PATTERNS OF CANNABINOID METABOLITES AFTER LAST USE IN A GROUP OF CHRONIC USERS [J].
ELLIS, GM ;
MANN, MA ;
JUDSON, BA ;
SCHRAMM, NT ;
TASHCHIAN, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (05) :572-578
[2]   Urinary excretion profiles of 11-nor-9-carboxy-Δ9-tetrahydropannabinol:: a Δ9-THC-COOH to creatinine ratio study #2 [J].
Fraser, AD ;
Worth, D .
FORENSIC SCIENCE INTERNATIONAL, 2003, 133 (1-2) :26-31
[3]   Urinary excretion profiles of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol Study III.: A Δ9-THC-COOH to creatinine ratio study [J].
Fraser, AD ;
Worth, D .
FORENSIC SCIENCE INTERNATIONAL, 2003, 137 (2-3) :196-202
[4]   Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: A cannabinoid-to-creatinine ratio study [J].
Fraser, AD ;
Worth, D .
THERAPEUTIC DRUG MONITORING, 2002, 24 (06) :746-750
[5]   Urinary Elimination of 11-Nor-9-Carboxy-Δ9-tetrahydrocannnabinol in Cannabis Users During Continuously Monitored Abstinence [J].
Goodwin, Robert S. ;
Darwin, William D. ;
Chiang, C. Nora ;
Shih, Ming ;
Li, Shou-Hua ;
Huestis, Marilyn A. .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2008, 32 (08) :562-569
[6]   Differentiating new marijuana use from residual drug excretion in occasional marijuana users [J].
Huestis, MA ;
Cone, EJ .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1998, 22 (06) :445-454
[7]   Urinary excretion profiles of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol in humans after single smoked doses of marijuana [J].
Huestis, MA ;
Mitchell, JM ;
Cone, EJ .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1996, 20 (06) :441-452
[8]   Urinary excretion half-life of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in humans [J].
Huestis, MA ;
Cone, EJ .
THERAPEUTIC DRUG MONITORING, 1998, 20 (05) :570-576
[9]  
HUNT CA, 1980, J PHARMACOL EXP THER, V215, P35
[10]  
LAFOLIE P, 1991, CLIN CHEM, V37, P1927